US2023263910A1PendingUtilityA1
Aav vectors targeted to the central nervous system
Assignee: UNIV NORTH CAROLINA CHAPEL HILLPriority: Nov 21, 2014Filed: Sep 21, 2022Published: Aug 24, 2023
Est. expiryNov 21, 2034(~8.3 yrs left)· nominal 20-yr term from priority
C12N 2750/14143A61P 25/00C12N 2830/008C12N 2750/14122C12N 2750/14145C12N 15/86C07K 14/005A61K 48/00A61K 48/0058A61K 35/76C12N 15/62A61K 31/711A61K 9/0014C12N 7/00C12N 2750/14121C12N 2750/14151A61K 31/7088A61P 21/00A61P 7/00
77
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to chimeric AAV capsids targeted to the central nervous system, virus vectors comprising the same, and methods of using the vectors to target the central nervous system. The invention further relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.
Claims
exact text as granted — not AI-modified1 . A nucleic acid encoding an AAV capsid, the nucleic acid comprising an AAV capsid coding sequence that is at least 70% identical to:
(a) the nucleotide sequence of any one of SEQ ID NOS:1-43; or (b) a nucleotide sequence encoding any one of SEQ ID NOS:44-86.
2 - 47 . (canceled)
48 . A nucleic acid encoding an AAV capsid, the nucleic acid comprising an AAV capsid coding sequence that is at least 70% identical to:
(a) the nucleotide sequence of any one of SEQ ID NOS:87-107; or (b) a nucleotide sequence encoding any one of SEQ ID NOS: 108-128.
49 - 138 . (canceled)
139 . A nucleic acid encoding an AAV8 capsid, the capsid comprising an E532K substitution.
140 - 171 . (canceled)Join the waitlist — get patent alerts
Track US2023263910A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.